K-V Pharmaceutical (KV.A +22%) soars following a brief halt after it says information from two...

|About: KV Pharmaceutical Co. (KV.B)|By:, SA News Editor

K-V Pharmaceutical (KV.A +22%) soars following a brief halt after it says information from two distinguished medical research bodies confirm that its FDA-approved Makena and unapproved compounded 17P formulations are not identical. The update clears previous concerns that were used by insurers to deny coverage for Makena prescriptions.